Short answer: Segment US biotech and pharma accounts by company stage (early-stage startup, clinical-stage, commercial-stage or large pharma) and by hub, such as Boston-Cambridge, the San Francisco Bay Area, San Diego, the New Jersey and Philadelphia corridor, and North Carolina's Research Triangle. Map both scientific and business buyers, find and verify emails and phones, and write outreach that respects how busy and regulated this industry is. Follow CAN-SPAM for email and consider TCPA and applicable privacy laws for calls.
Why biotech and pharma need a tailored approach
Life sciences companies differ widely. A ten-person preclinical startup buys very differently from a global pharma company with formal procurement and vendor qualification steps. Buyers are often scientists or operators with limited time, and many organizations have strict rules on vendor communication. Generic SaaS-style outreach tends to miss.
Step 1: Segment by stage
| Stage | Typical traits | Common buyers |
|---|---|---|
| Early-stage startup | Small team, founder-led, recently funded | Founder or CEO, CSO, Head of Operations |
| Clinical-stage | Running trials, growing headcount | VP Clinical Operations, Head of Regulatory, CFO |
| Commercial-stage | Products on market, sales and marketing teams | VP Commercial, Head of Market Access, VP Sales |
| Large pharma | Global, formal procurement | Category Manager, Director of Procurement, business unit leaders |
Match your product to the stage where you solve a real problem.
Step 2: Focus on US hubs
Life sciences activity is concentrated in a few regions:
- Boston and Cambridge, Massachusetts: a dense cluster of biotech startups, research institutions and large pharma research sites
- San Francisco Bay Area: biotech, genomics, tools and diagnostics companies
- San Diego: biotech, genomics and medical devices
- New Jersey and Philadelphia: large pharma, contract organizations and cell and gene therapy companies
- Research Triangle, North Carolina: pharma manufacturing, contract research and biotech
- Maryland and the Washington, DC area: biotech and government research links
Tag accounts by hub so you can tailor timing, events and messaging.
Step 3: Build account lists
Combine:
- Company searches filtered by industry, headcount and location
- Public funding announcements and press releases
- Clinical trial registries, to see which companies are running trials in your area of focus
- Conference exhibitor and sponsor lists for major life sciences events
- Your CRM history for lookalike customers
Step 4: Map the buying group
Biotech and pharma purchases often involve:
- A scientific or technical lead who evaluates fit
- An operations or business leader who owns budget
- Quality, regulatory or IT stakeholders who review risk
- Procurement, especially at larger companies
Map two to four contacts per account. For tools that touch regulated data or processes, expect quality and IT review to be part of the process.
Step 5: Find and verify contact details
- Use a contact finder you have tested on a sample of life sciences accounts
- Verify emails and pilot-send small batches before scaling
- Dial-test a sample of direct numbers
- Remove contacts who have left; movement between biotechs is common, especially after funding changes or restructurings
- Record the source of each contact
Step 6: Write relevant outreach
- Reference the company's stage, therapeutic area or recent public milestone you can verify
- Be precise and avoid hype; scientific buyers are skeptical of vague claims
- Offer something useful, such as a short relevant resource or a focused conversation
- Keep follow-ups spaced out and respectful
Never make claims about outcomes you cannot back up, and avoid anything that could look like you are discussing patient data.
Step 7: Measure and refine
Track usable contact rate, replies and meetings by stage and hub. Early-stage startups may respond faster, while large pharma may take longer but involve bigger deals.
Compliance (high level)
Follow CAN-SPAM for commercial email. For calls or texts to mobile numbers, consider TCPA and do-not-call rules. Life sciences companies may have their own policies on vendor contact, and applicable privacy laws may apply depending on what data your product handles. Get legal advice for your specific program.
Common mistakes
- Treating a seed-stage biotech like a large pharma company
- Using generic tech buzzwords with scientific buyers
- Ignoring quality, regulatory and IT stakeholders
- Relying on stale lists after funding changes or layoffs
- Over-following up with busy researchers
Where PeakAI fits
PeakAI is a contact finder with a Chrome extension that finds phone numbers, work emails and personal emails from professional profiles, drawing on global sources, with bulk export and integrations. After you segment US biotech and pharma accounts and map the buying group, use PeakAI or another tested finder to pull contacts, then verify before outreach. Run the same sample through each candidate tool and compare usable contacts and workflow fit. Check thepeakai.com for current features, coverage and pricing.
FAQ
Who should I contact first at a biotech startup?
At early-stage companies, founders, the CEO or the Chief Scientific Officer often make or heavily influence purchases. As companies grow, operations and functional leaders take on more of that role.
How is selling to large pharma different?
Large pharma usually has formal procurement, vendor qualification and security or quality reviews. Expect longer cycles and more stakeholders.
Which US regions have the most biotech companies?
Boston-Cambridge, the San Francisco Bay Area, San Diego, the New Jersey and Philadelphia corridor and the Research Triangle are commonly cited hubs.
How can I find biotech companies that are growing?
Look at public funding announcements, clinical trial registries, hiring activity and conference participation, then confirm details before you reach out.
Should I mention clinical results in outreach?
Only reference public information you can verify, and avoid implying anything about patient data or outcomes you cannot support.
